PE20140750A1 - Tratamiento del mieloma multiple - Google Patents
Tratamiento del mieloma multipleInfo
- Publication number
- PE20140750A1 PE20140750A1 PE2013002426A PE2013002426A PE20140750A1 PE 20140750 A1 PE20140750 A1 PE 20140750A1 PE 2013002426 A PE2013002426 A PE 2013002426A PE 2013002426 A PE2013002426 A PE 2013002426A PE 20140750 A1 PE20140750 A1 PE 20140750A1
- Authority
- PE
- Peru
- Prior art keywords
- multiple myeloma
- subject
- myeloma cells
- prevalence
- administer
- Prior art date
Links
- 208000034578 Multiple myelomas Diseases 0.000 title abstract 5
- 206010035226 Plasma cell myeloma Diseases 0.000 title abstract 5
- -1 CYT387 COMPOUND Chemical class 0.000 abstract 1
- 108090001005 Interleukin-6 Proteins 0.000 abstract 1
- GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 abstract 1
- 229960001467 bortezomib Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 abstract 1
- 229960001924 melphalan Drugs 0.000 abstract 1
- ZVHNDZWQTBEVRY-UHFFFAOYSA-N momelotinib Chemical compound C1=CC(C(NCC#N)=O)=CC=C1C1=CC=NC(NC=2C=CC(=CC=2)N2CCOCC2)=N1 ZVHNDZWQTBEVRY-UHFFFAOYSA-N 0.000 abstract 1
- 229950008814 momelotinib Drugs 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
- 230000035899 viability Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Abstract
SE REFIERE A UN METODO PARA TRATAR UN SUJETO QUE PRESENTA MIELOMA MULTIPLE EN UN ESTADIO CARACTERIZADO POR UN AUMENTO EN LA PREVALENCIA DE CELULAS DE MIELOMA MULTIPLE QUE SON NO RESPONDEDORAS A IL-6 O TIENEN UN FENOTIPO CD45-, EN DONDE EL METODO COMPRENDE: A) SELECCIONAR UN SUJETO DIAGNOSTICADO CON UN AUMENTO EN LA PREVALENCIA DE CELULAS DE MIELOMA MULTIPLE; B) ADMINISTRAR AL SUJETO UNA CANTIDAD DEL COMPUESTO CYT387 QUE ES N-(CIANOMETIL)-4-[2-[[4-(4-MORFOLINIL)FENIL]AMINO]-4-PIRIMIDINIL]-BENZAMIDA EFICAZ PARA REDUCIR LA VIABILIDAD DE DICHAS CELULAS DE MIELOMA MULTIPLE; Y C) ADMINISTRAR UN SEGUNDO AGENTE TERAPEUTICO TAL COMO MELFALAN Y BORTEZOMIB
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161481425P | 2011-05-02 | 2011-05-02 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20140750A1 true PE20140750A1 (es) | 2014-07-06 |
Family
ID=47107683
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2013002426A PE20140750A1 (es) | 2011-05-02 | 2012-05-01 | Tratamiento del mieloma multiple |
Country Status (20)
Country | Link |
---|---|
US (1) | US20140171433A1 (es) |
EP (1) | EP2704722A4 (es) |
JP (1) | JP2014514337A (es) |
KR (1) | KR20140081757A (es) |
CN (1) | CN103533939A (es) |
AP (1) | AP2013007281A0 (es) |
AU (1) | AU2012250491A1 (es) |
BR (1) | BR112013028420A2 (es) |
CA (1) | CA2834414A1 (es) |
CL (1) | CL2013003143A1 (es) |
CO (1) | CO6900134A2 (es) |
EA (1) | EA201391591A1 (es) |
IL (1) | IL228981A0 (es) |
MA (1) | MA35129B1 (es) |
MD (1) | MD20130089A2 (es) |
MX (1) | MX2013012785A (es) |
PE (1) | PE20140750A1 (es) |
SG (1) | SG194212A1 (es) |
WO (1) | WO2012149602A1 (es) |
ZA (1) | ZA201308918B (es) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101566840B1 (ko) | 2007-03-12 | 2015-11-06 | 와이엠 바이오사이언시즈 오스트레일리아 피티와이 엘티디 | 페닐 아미노 피리미딘 화합물 및 이의 용도 |
US8809359B2 (en) | 2012-06-29 | 2014-08-19 | Ym Biosciences Australia Pty Ltd | Phenyl amino pyrimidine bicyclic compounds and uses thereof |
US10363260B2 (en) | 2014-05-28 | 2019-07-30 | Oncotracker, Inc. | Anti-cancer effects of JAK2 inhibitors in combination with thalidomide derivatives and glucocorticoids |
TWI729644B (zh) | 2014-06-12 | 2021-06-01 | 美商西爾拉癌症醫學公司 | N-(氰基甲基)-4-(2-(4-𠰌啉基苯基胺基)嘧啶-4-基)苯甲醯胺 |
JP6986965B2 (ja) | 2014-07-22 | 2021-12-22 | アポロミクス インコーポレイテッド | 抗pd−1抗体 |
WO2016022630A1 (en) | 2014-08-05 | 2016-02-11 | Jiping Zha | Anti-pd-l1 antibodies |
CN106316963B (zh) * | 2015-06-26 | 2021-06-08 | 苏州泽璟生物制药股份有限公司 | 吗啡啉苯基氨基嘧啶化合物或其盐的多晶型物 |
CN105837515B (zh) * | 2016-04-06 | 2018-08-03 | 中国药科大学 | 一种JAK抑制剂Momelotinib的制备方法 |
CN106075046A (zh) * | 2016-07-31 | 2016-11-09 | 孙书芳 | 一种治疗肝肾阴虚型多发性骨髓瘤的中药 |
US10487321B2 (en) * | 2016-09-29 | 2019-11-26 | PZM Diagnostics, LLC | Method of extraction of genomic DNA for molecular diagnostics and application |
US20200209247A1 (en) * | 2017-09-15 | 2020-07-02 | University Of Iowa Research Foundation | Methods for identifying myeloma tumor-initiating cells and targeted therapy |
CN109045040A (zh) * | 2018-03-12 | 2018-12-21 | 首都医科大学附属北京天坛医院 | Cyt387用于制备治疗神经胶质瘤的药物的应用 |
CN111100076A (zh) * | 2019-12-30 | 2020-05-05 | 武汉九州钰民医药科技有限公司 | Jak抑制剂莫美洛替尼的制备方法 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080267905A1 (en) * | 2004-05-05 | 2008-10-30 | Celgene Corporation | Methods and Compositions Using Selective Cytokine Inhibitory Drugs for Treatment and Management of Cancers and Other Diseases |
KR20090093965A (ko) * | 2006-11-27 | 2009-09-02 | 아레스 트레이딩 에스.에이. | 다발성 골수종의 치료 |
KR101566840B1 (ko) * | 2007-03-12 | 2015-11-06 | 와이엠 바이오사이언시즈 오스트레일리아 피티와이 엘티디 | 페닐 아미노 피리미딘 화합물 및 이의 용도 |
-
2012
- 2012-05-01 CN CN201280021432.XA patent/CN103533939A/zh active Pending
- 2012-05-01 US US14/115,084 patent/US20140171433A1/en not_active Abandoned
- 2012-05-01 KR KR1020137030119A patent/KR20140081757A/ko not_active Application Discontinuation
- 2012-05-01 SG SG2013077607A patent/SG194212A1/en unknown
- 2012-05-01 AU AU2012250491A patent/AU2012250491A1/en not_active Abandoned
- 2012-05-01 EP EP12779619.1A patent/EP2704722A4/en not_active Withdrawn
- 2012-05-01 JP JP2014508647A patent/JP2014514337A/ja active Pending
- 2012-05-01 AP AP2013007281A patent/AP2013007281A0/xx unknown
- 2012-05-01 WO PCT/AU2012/000462 patent/WO2012149602A1/en active Application Filing
- 2012-05-01 MD MDA20130089A patent/MD20130089A2/ro not_active Application Discontinuation
- 2012-05-01 MX MX2013012785A patent/MX2013012785A/es unknown
- 2012-05-01 PE PE2013002426A patent/PE20140750A1/es not_active Application Discontinuation
- 2012-05-01 BR BR112013028420A patent/BR112013028420A2/pt not_active IP Right Cessation
- 2012-05-01 CA CA2834414A patent/CA2834414A1/en not_active Abandoned
- 2012-05-01 EA EA201391591A patent/EA201391591A1/ru unknown
-
2013
- 2013-10-21 IL IL228981A patent/IL228981A0/en unknown
- 2013-10-30 CL CL2013003143A patent/CL2013003143A1/es unknown
- 2013-11-20 MA MA36455A patent/MA35129B1/fr unknown
- 2013-11-27 ZA ZA2013/08918A patent/ZA201308918B/en unknown
- 2013-11-27 CO CO13278782A patent/CO6900134A2/es not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
CA2834414A1 (en) | 2012-11-08 |
US20140171433A1 (en) | 2014-06-19 |
WO2012149602A1 (en) | 2012-11-08 |
AP2013007281A0 (en) | 2013-11-30 |
EA201391591A1 (ru) | 2014-12-30 |
CN103533939A (zh) | 2014-01-22 |
AU2012250491A1 (en) | 2013-05-02 |
CO6900134A2 (es) | 2014-03-20 |
BR112013028420A2 (pt) | 2017-01-24 |
MD20130089A2 (ro) | 2014-05-31 |
JP2014514337A (ja) | 2014-06-19 |
MA35129B1 (fr) | 2014-05-02 |
EP2704722A4 (en) | 2014-11-05 |
KR20140081757A (ko) | 2014-07-01 |
IL228981A0 (en) | 2013-12-31 |
CL2013003143A1 (es) | 2014-07-04 |
MX2013012785A (es) | 2014-05-28 |
EP2704722A1 (en) | 2014-03-12 |
ZA201308918B (en) | 2014-08-27 |
SG194212A1 (en) | 2013-11-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20140750A1 (es) | Tratamiento del mieloma multiple | |
BR112012023021A2 (pt) | compostos de indazol e seus usos | |
EA201491008A1 (ru) | Комбинация антагониста crth2 и ингибитора протонного насоса для лечения эозинофильного эзофагита | |
BR112015022197A2 (pt) | tratamento de cataplexia | |
EA201590457A1 (ru) | Сульфамоил-ариламиды и их применение в качестве лекарственных препаратов для лечения гепатита b | |
AR094740A1 (es) | Antiadhesión de leucocitos para mitigar los potenciales eventos adversos causados por los dominios de unión específicos de cd3 | |
MX2013008192A (es) | Inhibidores de bace-2 para tratamiento de transtornos metabolicos. | |
EA201690754A1 (ru) | Применение ингибитора pcsk9 для лечения гиперлипидемии | |
EA201490004A1 (ru) | Применение bifidobacterium lactis bl-04 для лечения заболеваний дыхательных путей | |
UA115427C2 (uk) | Бензиламінові похідні як інгібітори калікреїну плазми | |
MX2014008021A (es) | Compuestos de fenil carbamato para usarse en aliviar o tratar el dolor. | |
BR112014014529A2 (pt) | métodos para melhorar terapias médicas | |
EA201490378A1 (ru) | ЛЕЧЕНИЕ РАССЕЯННОГО СКЛЕРОЗА С ИСПОЛЬЗОВАНИЕМ КОМБИНАЦИИ ЛАХИНИМОДА И ИНТЕРФЕРОНА-β | |
MX343931B (es) | Tratamiento de la esclerosis lateral amiotrofica con el uso de celulas derivadas del cordon umbilical. | |
UA113627C2 (xx) | Кристалічна форма циклоспорину a, фармацевтична композиція та спосіб лікування | |
EA201400002A1 (ru) | Способы лечения заболеваний сетчатки | |
PE20150709A1 (es) | Benzamidas | |
EA201690039A1 (ru) | Ингибиторы rorc2 и способы их применения | |
EA201491500A1 (ru) | Способы лечения фиброза | |
MX2015008187A (es) | Inhibidores de alk deuterados. | |
EA201490495A1 (ru) | Новые легкоразрушающиеся ингибиторы rock | |
EA201591507A1 (ru) | Лечение рассеянного склероза лахинимодом | |
MX2014005749A (es) | Nanoportadores terapeuticos y/o de diagnostico, dirigidos a metaloproteinasa de matriz (mmp). | |
GT201400306A (es) | Formas de administración farmacéuticas que comprenden 5-cloro-n-({(5s)-2-oxo-3-[4-(3-oxo-4-morfolinil)fenil]-1,3-oxazolidin-5-il}metil)-2-tiofencarboxamida | |
BR112014004879A2 (pt) | uso de inibidor de aromatase para tratamento de hipogonadismo e doenças relacionadas |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FD | Application declared void or lapsed |